Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sjors M Kas

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Scientific Reports|October 17, 2023
Functional classification of DDOST variants of uncertain clinical significance in congenital disorders of glycosylationSjors M Kas, Piyushkumar A Mundra, Duncan L Smith, et al.
Nucleic Acids Research|June 3, 2017
Identifying transposon insertions and their effects from RNA-sequencing dataJulian R de Ruiter, Sjors M Kas, Eva Schut, et al.
Oncoimmunology|March 3, 2020
Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune systemSjoerd Klarenbeek, Chris W Doornebal, Sjors M Kas, et al.
Cancer Research|August 18, 2018
Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547Sjors M Kas, Julian R de Ruiter, Koen Schipper, et al.
Nature Genetics|June 27, 2017
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinomaSjors M Kas, Julian R de Ruiter, Koen Schipper, et al.
Genes & Development|June 25, 2016
Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary glandStefano Annunziato, Sjors M Kas, Micha Nethe, et al.
Cancer Research|June 24, 2025
The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2Daniel Zingg, Chi-Chuan Lin, Julia Yemelyanenko, et al.
Nature|August 2, 2019
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasisMax D Wellenstein, Seth B Coffelt, Danique E M Duits, et al.
Nature|August 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Scientific Reports|October 17, 2023
Functional classification of DDOST variants of uncertain clinical significance in congenital disorders of glycosylationSjors M Kas, Piyushkumar A Mundra, Duncan L Smith, et al.
Nucleic Acids Research|June 3, 2017
Identifying transposon insertions and their effects from RNA-sequencing dataJulian R de Ruiter, Sjors M Kas, Eva Schut, et al.
Oncoimmunology|March 3, 2020
Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune systemSjoerd Klarenbeek, Chris W Doornebal, Sjors M Kas, et al.
Cancer Research|August 18, 2018
Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547Sjors M Kas, Julian R de Ruiter, Koen Schipper, et al.
Nature Genetics|June 27, 2017
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinomaSjors M Kas, Julian R de Ruiter, Koen Schipper, et al.
Genes & Development|June 25, 2016
Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary glandStefano Annunziato, Sjors M Kas, Micha Nethe, et al.
Cancer Research|June 24, 2025
The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2Daniel Zingg, Chi-Chuan Lin, Julia Yemelyanenko, et al.
Nature|August 2, 2019
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasisMax D Wellenstein, Seth B Coffelt, Danique E M Duits, et al.
Nature|August 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Pageof 1